Getting your player ready...
WASHINGTON — Pharmaceutical companies eager to keep less-expensive alternatives to their drugs off the market are increasingly reaching legal agreements with generic-drug makers to accomplish that goal, a government agency said Wednesday.
The Federal Trade Commission says that by jamming the pipeline for cheaper drugs, such agreements harm consumers. The agency has sued to block some settlements and is supporting legislation in Congress that would ban the practice.
